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Abstract
The renin‑angiotensin‑aldosteron system (RAAS) is a 
hormonal system that contributes to regulation of blood 
pressure and volume of extracellular fluids, in both nor‑
motensive and hypertensive individuals. Hypertension 
affects the target organs (kidneys) and leads to a vicious 
circle that contributes to maintaining a high arterial pre‑
ssure. Besides the hemodynamic effects of RAAS/Ang II, 
Ang II has direct impact on structure/function of kidneys, 
leading  to  renal  injury.  Recently,  the  proinflammatory 
effect of Ang II has been discovered. Low renal inflamma‑
tion determined by excessive circulating RAAS, mostly at 
renal level, promotes and continues the renal disease. This 
review presents the inflammatory mechanisms initiated by 
Ang II at renal level, which induce development of renal 
injury. Identification of such mechanisms might lead to the 
discovery of new therapeutic approaches for hyperten‑
sion/target organs damage. 
Keywords: RAAS, inflammation, renal injury, hyperten‑
sion
I. THE RENIN‑ANGIOTENSIN‑ALDOSTE‑
RON SYSTEM
Increased RAAS (renin‑angiotensin‑aldosteron 
system) activity, particularly at angiotensin II 
(Ang II) levels, contributes to target organ dam‑
age and increases the risk of cardiovascular 
events by increasing blood pressure, as well as 
by its direct effect on the vascular endothelium 
and cardiac and renal tissues [1], stimulating the 
inflammatory phenomena and the development 
of atherosclerosis [2]. Hypertension is closely 
related to renal disfunctions [3] and represents 
both the cause and effect of kidney diseases.
In 1871, Traube hypothesized that hyperten‑
sion may be a homeostatic response threatening 
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the excretory function of the kidney [4]. Exces‑
sive secretion of Ang II (antinatriuretic hormone) 
induces a transient increase in sodium retention. 
Physiologically, sodium retention becomes nor‑
mal in a few days, but there are situations when 
it is maintained at a high level, causing hyperten‑
sion. Ang II reduces the renal ability to excrete 
sodium and initiates a series of events that lead 
to increased blood pressure [5]. Increase in blood 
pressure, required to return to normal sodium 
excretion, is achieved by pressure – natriuresis 
phenomenon. The peripheral vascular resistance 
often increases in hypertension, although 
increased blood pressure is initiated by sodium 
retention and expansion of volume replacement. 
Increased blood pressure occurs due to direct 
and indirect effects of peripheral vasoconstrictor 
Ang II. Chronic administration of Ang II leads to 
increased sodium retention, developing severe 
systemic hypertension and pulmonary oedema.
Classically, the renin angiotensin system was 
considered a circulating hormone structure 
whose final and bioactive product, Ang II, is pro‑
duced with the participation of two important 
enzymes, renin and the angiotensin‑converting 
enzyme [6]. The renin‑angiotensin system is a 
hormonal complex with paracrine, autocrine and 
intracrine properties. Angiotensine is formed by 
the action of renin on its specific substrate, angi‑
otensinogen, through a cascade of enzymatic 
reactions. Renin, a glycosylated carboxypepti‑
dase secreted by the renal juxtaglomerular cells, 
acts on angiotensinogen (a complex macromo‑
lecular protein released by hepatocytes) to form 
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angiotensin I (an apparently inactive decapep‑
tide). Angiotensin I is converted into a biologi‑
cally active molecule – angiotensin II (8 
amino acids) by the action of a glycoprotein 
released by lung tissue, the angiotensin‑convert‑
ing enzyme (ACE). Recently, a homologous angi‑
otensin‑converting enzyme called ACE2 was 
found in heart, kidney, liver, intestine. This new 
converting enzyme produces the hydrolysis of 
the last aminoacid of angiotensin I, leading to 
angiotensin (1‑9), a classical inhibitor of ACE1 
and a precursor of angiotensin (1‑7). Angioten‑
sin‑(1‑9) may limit the formation and actions of 
angiotensin  II,  contributing  to  local  traffic 
self‑regulation [6]. Also, angiotensin II can be 
generated from angiotensin I by the action of a 
large number of peptidases called chimase (alter‑
native ways of Ang II formation) [7]. As other 
peptide hormones, the angiotensins bind to 
membrane receptors on target cells to exercise 
their actions (type 1‑AT1 and type 2‑AT2 angio‑
tensin receptors). Classically, the most important 
function of RAAS is to maintain blood pressure 
by Ang II‑induced vasoconstriction and sodium 
retention, mediated by aldosterone in renal col‑
lecting tubules [8].
II. INTRARENAL RENIN‑ANGIOTENSIN 
SYSTEM
After more than two decades, a local RAAS 
that acts independently on the systemic RAAS 
has been described [9]. An exact delineation of 
the contribution of local and systemic angioten‑
sin peptides is difficult in terms of recent exper‑
iments. Every system in the body contains 
elements of RAAS. The excretory system (kid‑
neys) is the only one that possesses all RAAS 
components. In the last decade, Ang II is consid‑
ered a multifunctional cytokine with multiple 
non‑hemodynamic properties [10]. In addition to 
electrolytes homeostasis control, Ang II mediates 
several key events in inflammatory processes 
[11]. In inflammatory processes, local RAAS acti‑
vation and synthesis of Ang II leads to increased 
vascular permeability by VEGF secretion (vascu‑
lar endothelium‑derived growth factor) [12‑14] 
and induces the expression of adhesion molecu‑
les (L – selectins, P – selectins and ICAM‑1) and 
their ligands (integrins) [15‑17]. Ang II promotes 
inflammatory cell infiltration of tissues by stimu‑
lating the production of cytokines / chemokines.
The renin angiotensin aldosterone system 
plays an essential role in pathological changes 
that lead to the progression of kidney disease. 
Renal injury activates directly and indirectly the 
local renin angiotensin aldosterone system. For 
example, hyperglycemia, proteinuria, reduced 
calcitriol can stimulate local Ang II synthesis 
[18]. Inflammation, an early stage of kidney dam‑
age,  is  followed  by  tubulointerstitial  fibrosis, 
tubular atrophy and glomerulosclerosis [19].
III. PROINFLAMMATOY EFFECTS 
OF RAAS
Mononuclear cell infiltration of the glomeruli 
and interstitium is present in most renal diseases 
and plays a crucial role in the development of 
irreversible structural changes. Immunocompe‑
tent cells (T lymphocytes, macrophages and den‑
dritic cells) contain components of the RAAS and 
contribute to the production of Ang II [20‑22]. 
RAAS plays an essential role in leukocyte infil‑
tration and thus it can influence the evolution of 
many renal diseases associating immune activa‑
tion [23].
Ang II is involved in inflammatory processes 
occurring during kidney damage by regulating 
the expression of adhesion molecules. Ang II is 
a  chemotatic  factor  for  inflammatory  cells, 
increasing the expression of chemokines and 
chemokine receptors in both resident cells and 
infiltrated cells [20]. The inflammatory response 
can be direct ‑ through the production of MCP‑1 
and TGF‑β1, and indirect ‑ by activating resident 
cells by macrophages released factors [24].
By AT 1 and AT 2 receptors pathways, Ang II 
stimulates transcription of the NF‑KB factor. 
Ang IV has a similar effect. Angiotensin receptor 
antagonists (sartans) can block only certain pro‑
inflammatory effects of RAAS. The NF‑KB factor 
activation caused by Ang II occurs via the Rho 
kinase way.
Ang II stimulates the Ets factor transcription 
that is the main regulator of vessel infiltration 
with T lymphocytes and macrophages / mono‑
cytes recruited by the vascular wall [25]. Another 190 volume 3 • issue 3 July / September 2013 •  pp. 188-194 
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mechanism involved in the development of renal 
inflammation in response to Ang II involves the 
participation of Toll‑like receptor 4 of mesangial 
cells. An increase in Toll‑like receptors 4, medi‑
ated by Ang II, results in activation of the NF‑KB 
factor [26].
The essential role in the progression of renal 
disease is played by recruitment of inflammatory 
cells in glomeruli and tubular interstitium. Ang 
II stimulates the growth of VECAM‑1 number 
(vascular cell adhesion molecule‑1), ICAM‑1 
(intercellular adhesion molecule‑1), and integ‑
rins, and allows the circulating immune cells to 
adhere to the capillaries.
The NF‑KB factor mediates the transcription 
of chemokine genes responsible for the renal tis‑
sue leukocytes infiltration, that include: MCP‑1 
(monocyte chemotactic protein‑1), RANTES.
Ang II can directly stimulate cell proliferation 
[27]. Leukocytes are an active source of Ang II, 
thus  amplifying  the  proinflammatory  effects 
[28]. Ang II‑mediated proinflammatory effects 
increase the pathophysiological changes caused 
by proteinuria [10].
III.1. THE ROLE OF ANGIOTENSIN 
AND NF‑KB FACTOR IN THE 
INFLAMMATORY RESPONSE
Ang II plays a special role in the development 
of inflammation in the kidney. The main vasoac‑
tive peptide of RAAS causes migration and 
adherence of the circulating immune cells in the 
kidney, at both endothelial and mesangial level. 
This process involves adhesion of the cytokines 
and chemokines molecules [29]. On experimen‑
tal animal models with kidney diseases, admin‑
istration of angiotensin converting enzyme 
inhibitors (ACEI) results in decreased cell infil‑
tration and inflammatory markers [29].
By activating the AT1 receptor, Ang II increases 
the  expression  of  proinflammatory  genes  for 
VCAM‑1, ICAM‑1, IL‑6 and MCP‑1. The signal‑
ing pathways by which these effects are achieved 
include activation of the NF‑KB factor, MAP‑ 
kinase cascade, Rho protein and redox pathways.
Experimental data show that AT2 receptors 
are involved in the activation of inflammatory 
cells in the kidney. The AT2 receptor antagonists, 
but not the AT1 receptor, decrease the number 
of inflammatory cells in two animal models of 
unilateral urethral obstruction receiving sys‑
temic Ang II [29‑31].
The combined treatment with AT1 and AT2 
receptor antagonists inhibits the inflammatory 
response by two mechanisms: decrease of cell 
infiltrate and decreased expression of proinflam‑
matory genes.
On unilateral urethral obstruction model, 
blocking of the AT2 receptor decreases TNF‑α 
and expression of RANTES; stimulation of both 
types of receptors decreases gene expression, 
which increases MCP‑1 [30]. Involvement of 
NF‑KB is known in renal disease. In vivo activa‑
tion of the NF‑KB factor, produced as a response 
to Ang II, is partially diminished by AT1 and 
AT2 receptor antagonists. In contrast, simultane‑
ous administration of both types of receptor 
antagonists or ECAI totally abolishes this 
response [29‑31]. The NF‑KB factor activation in 
the kidney is differently mediated, according to 
the place where it occurs. Therefore, in mesan‑
gial cells, it is mediated by both types of recep‑
tors, in tubulo‑interstitial cells only by AT1 
receptors, while, in the endothelial cells ‑ via the 
AT2 receptor.
On the unilateral urethral obstruction model, 
blocking of the renal NF‑KB factor activation by 
treatment with two different renal inhibitors 
(pyrrolidin dihydrocarbonate and partenolide) 
decreases the infiltration with inflammatory cells 
and the gene expression of some pro‑inflamma‑
tory factors.
In spontaneously hypertensive rats, inhibition 
of the NF‑KB factor results in the decrease of 
infiltration with inflammatory cells in renal inter‑
stitium and normalization of blood pressure. 
These data support the hypothesis that, in some 
experimentally‑induced renal disease, blocking 
of Ang II with ACEI and antagonists of angio‑
tensinic receptors (AT1 and AT2), and inhibition 
of NF‑KB pathways are necessary to stop the 
inflammatory processes.
In conclusion, drugs that modulate the activ‑
ity of the RAAS, such as ACEI and AT1 receptor 
antagonists, have a protective effect on the kid‑
ney. International Journal of Medical Dentistry 191
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III.2. INFLAMMATION AND RENAL 
INTERSTITIUM
Ang II acts as a cytokine mediating the infil‑
tration and activation of immunocompetent cells 
in the renal interstitium. Immunocompetent cell 
infiltration of the renal interstitium is present in 
non‑immune primary injury (the disease evolves 
with proteinuria, urinary obstruction, polycystic 
kidney disease, diabetes, hypertension). Mono‑
nuclear cell infiltration occurs in the absence of 
a specific antigen and is the result of increased 
expression of chemoatractant molecules [22,23].
Under pathological conditions, an increased 
activation of the RAAS, especially in the tubular 
cells, may be observed. A decrease in renal inter‑
stitium infiltration is achieved by blocking the 
RAAS (antisense oligonucleotides and drugs). 
This phenomenon is partially due to decreasing 
of chemokines (MCP‑1 and osteopontin), adhe‑
sion molecules and other mediators. Ang II pos‑
sesses chemotatic properties for mononuclear 
cells. Tubular RAAS activation leads to an 
increase in local interstitial infiltration. Mice with 
a deficit of AT1 receptor and a high level of pro‑
teinuria show a marked interstitial infiltration, 
that is not reduced after ACEI administration. 
Instead, there is a significant decrease in cellular 
infiltration after an antagonist of A/B endothelin 
receptor administration. Ang II stimulates the 
expression of endothelium. This suggests that 
other mediators, including vasoactive peptides, 
endothelin, are involved in interstitial cell recruit‑
ment [32].
Johnson et al. hypothesized that sodium‑sen‑
sitive hypertension appears as the result of tub‑
ulo‑interstitial damage, interferring with the 
physiological mechanisms of pressure‑natriure‑
sis type. This phenomenon has been studied 
extensively by the use of Ang II in hypertensive 
models, due to a massive intake of sodium. The 
conclusion was that Ang II is the key mediator 
involved in cell recruitment. Administration of 
mycophenolate mofenil prevents this type of 
hypertension and markedly reduces cell infiltra‑
tion of the interstitium [33].
Chronic administration of L‑NAME reduces 
the synthesis of nitric oxide and the development 
of hypertension. At interstitial level, an infiltra‑
tion with macrophages and lymphocytes occurs. 
When the chronic L‑NAME administration is 
interrupted, normalization of blood pressure is 
observed, to a lower extent for the animals hav‑
ing received a hypersodate diet during hyperten‑
sion. Interestingly, both sodium‑dependent 
hypertension models showed a high level of Ang 
II‑producing cells, particularly lymphocytes, 
accumulated in the renal interstitium. Adminis‑
tration of mycophenolate mofenil led to stabili‑
zation of blood pressure and decrease of oxidative 
stress [34].
In conclusion, the immune cells are capable of 
producing Ang II in various stages of renal 
impairment, playing therefore an important role 
in sodium‑sensitive hypertension [35].
The immunocompetent cells recruited by the 
inflammed interstium can synthesize Ang II that 
locally induces differentiation of antigen pre‑
senting cells and increases their antigenic activ‑
ity.
III.3. INFLAMMATION AND RENAL 
GLOMERULUS
Local  RAAS  amplifies  the  antigen‑specific 
immune response in renal glomerular diseases.
Ang II is involved in the pathogenesis of the 
immune complex mediated glomerulonephritis, 
by activating the NF‑KB factor, MCP‑1 produc‑
tion and expression of adhesion molecules 
[36‑38]. In glomerulonephritis, the renal RAAS 
mediates  antigen‑specific  T  cell  activation.  In 
anti‑glomerular basement membrane glomeru‑
lonephritis (anti‑GMB GN), both humoral and 
cellular immunity are involved. In acute glomer‑
ular injury, the immunoglobulin Fc receptor 
plays a critical role in PMN recruitment [39]. It 
was observed that mice deficient in Fc receptor 
[γ  (–/–)]  showed  protection  against  primary 
lethal injury, but still developed glomerular 
injury characterized by: mesangial proliferation, 
accumulation of macrophages and formation of 
deposits in the basement membrane. These 
changes are prevented by AT1 receptor antago‑
nists administration [35].
Under such conditions, an important role in 
the formation of glomerular basement mem‑
brane deposits is played by Th1 limphocytes. 
The antibodies, deposited on the glomerular 
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RASS in a dose‑dependent manner. In vivo and 
in vitro studies have demonstrated that Ang II 
plays an important role in lymphocytic prolif‑
eration, mostly of Th1 lymphocytes. However, 
the contribution of systemic RAAS to the devel‑
opment of glomerulonephritis mediated by T 
cells is not fully understood. There is a large 
functional diversity between Th1 and Th2 lym‑
phocytes, which is partially explained by the dif‑
ferent phenotypes of chemokine receptors [40]. 
Administration of Ang II in mesangial cells 
has a potent chemotatic effect for T cells. At this 
level, Ang II enhances the expression of 
chemokines IP‑10 and MIP1α.
In glomerulonephritis with immune com‑
plexes, local RAAS may contribute to the occur‑
rence  of  antigen‑specific  T  lymphocytes  in 
inflammated glomeruli. The mechanism under‑
lying this phenomenon is achieved, at least par‑
tially, through chemokines regulation. The 
appearance of cellular response to Ang II is 
achieved through different molecular pathways, 
which include calcium mobilization, generation 
of free radicals, activation of protein kinases and 
nuclear transcription factors [41].
Inflammatory processes caused by Ang II are 
achieved through the NF‑KB factor, which rep‑
resents the key mediator of these processes. 
Under its control, Ang II causes an increase in 
the cytokines and chemokines proinflammatory 
genes. The NF‑KB factor activation pathway 
involves both types of angiotensin receptors, 
AT1 and AT2. The pathways by which Ang II 
activates the Th1 type chemokines are differently 
regulated. IP‑10 is NF‑KB dependent, whereas 
MIP‑1α is regulated mainly by NF‑AT (nuclear 
factor calcineurin‑dependent on the T activated 
cells). The NF‑AT activity requires a higher con‑
centration of calcium, realized by a massive 
influx through calcium release‑dependent 
(ICRAC) and calcineurin‑ dependent (CaN) 
channels.
The NF‑AT pathway activated by Ang II may 
be involved in pathological changes of vascular 
smooth muscle cells. CaN / NF‑AT are involved 
in Ang II‑induced lymphocytic proliferation, 
while the Ang II / NF‑AT pathway might be 
involved in tubulo‑interstitial damage [42]. Acti‑
vation of NF‑AT was observed in tubulo‑inter‑
stitial infiltration of chronic glomerulonephritis 
with anti ‑ basement membrane antibodies and 
proteinuria in mice γ (–/–).
In conclusion, Ang II acts as a mediator of 
inflammation, being partially involved in the 
pathogenesis of kidney disease by infiltration 
and activation of immunocompetent cells. In 
some kidney diseases, the immune system can 
be directly influenced by local RAS activation.
PERSPECTIVES
The synthesis of the first oral inhibitor of ACE, 
captopril, urged the development of new thera‑
peutic hypotheses and opened a new stage in 
clinical research of RAAS. Blocking of RAAS 
with IACE has been showed as very efficient in 
the treatment of hypertension. Subsequently, the 
hypertensive patients benefit from the discovery 
of Ang II antagonists discovery, which selec‑
tively block the activation of AT1 receptors, 
without influencing vase‑dilatation kinines. Use 
of anti‑inflammatory medication or blocking of 
inflammatory  cytokines  in  hypertension  may 
represent a new therapeutic approach in renal 
disease.
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